A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART

AIDS

Volumn 17, Issue 10, 2003, Pages 1487-1492

  Fagard, Catherine ^a   Le Braz, Michelle ^a   Günthard, Huldrych ^b   Hirsch, Hans H ^c   Egger, Martin ^d   Vernazza, Pietro ^a   Bernasconi, Enos ^e   Telenti, Amalio ^f   Ebnöther, Corinna ^b   Oxenius, Annette ^g   Perneger, Thomas ^h   Perrin, Luc ^h   Hirschel, Bernard ^a,i  

^a Division of Infectious Diseases   (Switzerland)

^b Division of Infectious Diseases   (Switzerland)

^c Division of Infectious Diseases   (Switzerland)

^d Institute for Infectious Diseases   (Switzerland)

^e Divisions of Infectious Diseases   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g ETH ZURICH   (Switzerland)

^h UNIVERSITY HOSPITAL   (Switzerland)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiretroviral therapy interruption; Granulocyte macrophage colony stimulating factor

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EDEMA; ERYTHEMA; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INJECTION PAIN; LYMPHOCYTE COUNT; MALAISE; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HIV-1; HUMANS; PILOT PROJECTS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 10744226358     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307040-00009     Document Type: Article

References (38)

1. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study. JAMA 1999, 282:2220-2226.
2. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med 1997, 3:483-486.
3. Hirschel B, Fagard C, Le Braz M. The Swiss-Spanish intermittent trial. XIII International Conference on AIDS. Durban, July 2000 [abstract no. THOrB747].
4. Fagard C, Le Braz M, Guenthard H, et al. A prospective trial of strategic treatment interruptions in HIV infection. Arch Intern Med 2002, 163:1220-1226.
5. Oxenius A, Price DA, Guenthard H, Dawson S, Perrin L, Fagard C, et al. Impact of structured treatment interruptions in chronic HIV-1 infection on HIV-specific cellular immunity. Proc Natl Acad Sci USA 2002, 99:13747-13752.
6. Oxenius A, McLean A, Fischer M, Hafner R, Schneider C, Joller H, Price D, et al. Viral and HIV-specific CTL dynamics during intermittent antiretroviral therapy in chronically HIV-infected patients. J Virol 2002, 76:10169-10175.
7. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350-1356.
8. Arnó A, Ruiz L, Juan M, Jou A, Balaqué M, Zayat MK et al. Efficacy of low-close subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with less than or equal to 250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999, 180:56-60.
9. Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group [in process citation]. J Infect Dis 1998, 178:992-999.
10. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998, 12:F225-F234.
11. Levy Y, Capitant C, Houhou S, Carriere I, Viard J-P, Goujard C, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. Lancet 1999, 353:1923-1929.
12. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS. AIDS - Reemergence of HIV after stopping therapy. Nature 1999, 401:874-875.
13. Davey RT, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999, 96:15109-15114.
14. Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 1999, 19:114-120.
15. Ihata A, Watabe S, Shirai A, Fukushima J, Hamajima K, Inoue J, et al. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology 1999, 98:436-442.
16. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP. Dendritic cells infiltrating tumors cotranscluced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999, 190:125-133.
17. Diehl L, den Boer AT, Schoenberger SP, El van der Voort, TN Schumacher, CJ Melief, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med 1999, 5:774-779.
18. Glaspy JA, Golde DW. The colony-stimulating factors: biology and clinical use. Oncology 1990, 4:25-32.
19. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90:3539-3543.
20. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseky ES, et al. Granulocyte-Macrophage Colony-Stimulating Factor; An Effective Adjuvant for Protein and Peptide-Based Vaccines. Blood 1996, 88:202-210.
21. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaumes M, Jones TC. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996, 1199-1204.
22. Stripecke R, Skelton DC, Pattengale PK, Shimada H, Kohn DB. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther 1999, 10:2109-2122.
23. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSE)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
24. Kedzierska K, Maerz A, Warby T, Jaworowski A, Chan HT, Mak J, et al. Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages. AIDS 2000, 14:1739-1748.
25. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. AIDS Res Hum Retroviruses 1995, 11:1031-1038.
26. Perno CF, Cooney DA, Gao WY, Hao Z, Johns DG, Foli A, et al. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxy-nucleosides in cultures of monocyte/macrophages, Blood 1992, 80:995-1003.
27. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DS, Hao Z, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect medfated by 3′-azido-2′3′dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989, 169:933-951.
28. Brites C, Gilbert MJ, Pedral-Sampaio D, Bahia F, Pedroso C, Alcantara AP, et al. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS. J Infect Dis 2000, 182:1531-1535.
29. Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, et al. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. AIDS 2000, 14:387-395.
30. Skowron G, Stein D, Drusano G. The safety and efficacy of granuloyte-macrophage colony-stimulating factor (sargramostin) added to indinavir- or ritonavir-based antiretroviral therapy: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2002, 180:1064-1071.
31. Lori F, Foli A, Maserati R, Seminari E, Xu J, Whitman L, et al. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clin Trials 2002, 3:115-124.
32. Fleischmann J, Golde DW, Weisbart RH, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986, 68:708.
33. Ho AD, Haas R, Wulf G, Knauf W, Ehrhardt R, Heilig B, et al. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 1990, 75:203.
34. Perkins RC, Vadhan-Raj S, Scheule RK, Hamilton R, Holian A. Effects of continuous high dose rhGM-CSF on human monocyte activity. Am J Hematol 1993, 43.
35. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998, 92:4491-4508.
36. Kim KY, Kang MA, Nam MJ. Enhancement of natural killer cell-mediated cytotoxicity by coexpression of GM-CSF/B70 in hepatoma. Cancer Lett 2001, 166:33-40.
37. Matsuda S, Akagawa K, Honda M, Yokota Y, Takebe Y, Takemori T. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte/macrophage colony-stimulating factor. J Acquir Immune Def Hum Retrovirol 1996, 11:1031-1038.
38. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, Rouzioux C, et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. JAMA 1998, 279:277-280.